-
公开(公告)号：US20240216517A1
公开(公告)日：2024-07-04
申请号：US18289152
申请日：2022-05-03
申请人： CELLEMEDY CO., LTD
发明人： Jee Won LEE , Bo Ram LEE
CPC分类号： A61K47/64 , A61K45/06 , A61P35/00 , C07K16/2827
摘要： A protein has the molecule capable of binding to the immune checkpoint molecule fused to an outer surface thereof and thus may be used as an immune checkpoint inhibitor. A method for treating a lung cancer includes administering to a subject in need thereof a composition comprising a ferritin protein in which a molecule capable of binding to an immune checkpoint molecule is fused to an outer surface of the protein.
-
2.发明公开公开(公告)号：US20240148898A1
公开(公告)日：2024-05-09
申请号：US17773266
申请日：2020-11-02
申请人： CELLEMEDY CO., LTD
发明人： Jee Won LEE , Bo Ram LEE , Chul Joo YOON
IPC分类号： A61K47/69 , A61P35/00 , C07K14/47 , C07K14/705 , A61K38/00
CPC分类号： A61K47/6929 , A61P35/00 , C07K14/47 , C07K14/70521 , C07K14/70532 , A61K38/00
摘要： A ferritin protein according to an embodiment of the present disclosure has an outer surface on which a molecule configured to bind to an immune checkpoint molecule. The present invention relates to a protein used with a disease antigen and a use of same. The A ferritin protein is formed via self-assembly of ferritin monomers fused with a disease antigen epitope. The protein exhibits excellent binding affinity to a human transferrin receptor, and thus can provide various kinds of disease antigen epitopes with different lengths to antigen-presenting cells so as to induce an immune response to the corresponding antigen.
-
公开(公告)号：US20240218030A1
公开(公告)日：2024-07-04
申请号：US18289179
申请日：2022-05-03
申请人： CELLEMEDY CO., LTD
发明人： Jee Won LEE , Bo Ram LEE
CPC分类号： C07K14/47 , C07K16/084 , C07K16/2803 , C07K16/2806 , C07K16/2809 , C07K16/2818 , C07K16/2821 , C07K16/2827 , C07K16/2851 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2878 , C07K16/30 , C07K16/3007 , C07K16/3069 , C07K16/3084 , C07K16/3092 , C07K16/32 , C07K16/40 , C07K2319/30
摘要： A ferritin protein is mutated to have a foreign peptide fused to the outer surface thereof so that a binding force to a human transferrin receptor is reduced. The peptide can exhibit activities of various foreign peptides. The foreign peptide is a pharmacologically active peptide, and the foreign peptide may include a ligand or a fragment thereof, a receptor or a fragment thereof, an antibody or a fragment thereof including an antigen binding region (CDR), which are capable of binding to an immune checkpoint molecule; or a disease antigen epitope.
-
公开(公告)号：US20230391893A1
公开(公告)日：2023-12-07
申请号：US18034193
申请日：2021-11-01
申请人： CELLEMEDY CO.,LTD
发明人： Jee Won LEE , Bo Ram LEE , Chul Joo YOON
CPC分类号： C07K16/468 , C07K14/47 , C07K16/2827 , C07K16/2818 , C07K16/2803 , A61P35/00 , C07K2317/565 , C07K2319/735 , C07K2318/20 , C07K2317/31 , C07K2317/92 , A61K38/00
摘要： An antibody-like protein is formed by self-assembly of a plurality of ferritin monomers including at least CDR-ferritin monomers having a complementarity-determining region of an antibody fused thereto whereby the antibody-like protein has the complementarity-determining regions present at a high density on the surface or outside thereof so that even some of the complementarity-determining regions, such as HCDR3, etc., can bind to an antigen at an affinity level similar to that of the antibody, and the antibody-like protein possesses a structural feature advantageous for binding simultaneously to a plurality of antigens, and as such, has remarkably improved binding avidity, compared to the antibody. The antibody-like protein of the present invention is an antibody substitute that can be utilized in antibody-based uses and fields.
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
